A Phase 2 interventional study of Abrocitinib in Prurigo Nodularis, Pruritus and Chronic Pruritus, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.
Among the 163 studies in Pruritus with a site in United States, this one is the 127th largest by enrollment of the 153 interventional ones that give a count, is one of 8 that started in 2021, is one of 60 in phase 2, and was the 111th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Novartis Pharmaceuticals · Sites in United States, Canada, China
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Canada and 2 more countries
Ages 18+
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Integrative Skin Science and Research · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 69 · Phase 3 48 · Phase 4 13
First in 2000; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 70 across the 153 interventional studies, 80 across the 9 observational. Of the 126 that completed or were terminated, 80 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 163 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,816 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 5 studies filed under Pruritus — fewer than ten, so there is no comparison to draw.
12 of the studies in Pruritus with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT05263206Phase 3SanofiEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | 2027-06-02 |
| NCT07450716Massachusetts General HospitalAssessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT07074977Galderma R&DProof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 163 studies in Pruritus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe pruritus.
This is a trial to assess the efficacy of Abrocitinib as a therapeutic for Prurigo Nodularis (PN) and Chronic Pruritus of Unknown Origin (CPUO). The study will consist of a 4-week Screening period, a 12-week treatment period and then a 4-week follow up period. The arms will run in parallel and patients will take 200 mg oral Abrocitinib daily for the duration of the 12-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
Exclusion Criteria:
Have received any of the following treatment regiments specified in the timeframes outlined below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prurigo Nodularis (PN) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
Drug: Abrocitinib
Chronic Pruritus of Unknown Origin (CPUO) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
Drug: Abrocitinib
During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12
Percent change in weekly average PP-NRS at Week 12. PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.
Time frame: Up to 12 weeks
Number of Subjects Achieving a Reduction in Weekly Average PP-NRS From Baseline to Week 12
Number of subjects achieving at least a 4-point reduction from baseline in weekly average PP-NRS at Week 12. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.
Time frame: Up to 12 weeks
Itch Severity Assessed by 5-D Pruritus Scale at Baseline and Week 12
Assess itch severity as assessed by 5-D pruritus scale. The 5-D pruritus scale scores pruritus over the past 2 weeks along 5 dimensions: duration, degree, direction, disability and distribution. Duration, degree and direction are scored from 1 to 5, with "1" indicating better control and resolution of symptoms, and "5" indicating increased intensity, severity and worsening. Disability is assessed in Leisure/Social, housework/errands, and work/school with scores ranging from N/A, and 1-5, with "1" indicating that itch never affects the activity, and "5" meaning that itch always affects this activity. The scores of each of the 5 domains are achieved separately and then summed together to obtain a total score. Scores can range between 5 no pruritus, and 25 most severe pruritus.
Time frame: Baseline (week 0) and 12 weeks
Quality of Life as Assessed by the Dermatology Quality of Life Index From Baseline and Week 12
Quality of life as assessed by the Dermatology Quality of Life Index (DLQI). The DLQI is 10 questions used to assess impact of skin disease. Scores range from 0-30, with "0" corresponding to best quality of life, and "30" corresponding to worst quality of life.
Time frame: Baseline (week 0) and 12 weeks
Pruriginous Lesions as Assessed by the Prurigo Activity Score From Baseline and Week 12
Pruriginous lesions as assessed by the Prurigo Activity Score (PAS). The PAS is a 7-item questionnaire that assesses the number, distribution and activity of pruriginous lesions. The score is calculated via summation of the scoring values, added up with 123 and afterwards divided by 10. This results in a range of values from 1.3 to 21.3.
Time frame: Baseline (week 0) and 12 weeks
Itch-scratching Behavior as Assessed by Patient Reported Outcomes Measurement Information System at Baseline and Week 12
Itch-scratching behavior as assessed by Patient Reported Outcomes Measurement Information System (PROMIS®) Itch Questionnaire (PIQ) T-Score: Scratching. The PIQ T-Score: Scratching, is comprised of 5 questions to assess Itch-Scratching Behavior over the past 7 days. Scores for each question range from 1-5, Score range of 5-25 with scores of "1" indicating less scratching behavior and scores of "5" indicating the greatest scratching behavior. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Itch, a T-score of 60 is one SD worse than average. By comparison, an Itch T-score of 40 is one SD better than average For PROMIS, the T-scores have a mean (SD) of 50 (10) for adults in the US experiencing itch for any reason.
Time frame: Baseline (week 0) and 12 weeks
Number of Nodules at Baseline and Week 12
Number of baseline prurigo nodules over time. As part of the Prurigo Activity Score, lesions are counted in a representative body region. Lesion count within the representative area at Week 0 was compared to lesion count in the representative area at Week 12.
Time frame: Baseline (week 0) and 12 weeks
Prurigo Nodule Severity at Baseline and Week 12
Prurigo nodule severity using the Investigator's Global Assessment (IGA). The IGA is a physician scale assessing the number of nodules a Prurigo Nodularis (PN) patient has. Patients receive a score between 0 and 4, where "0" is clear: "No prurigo nodules. Post-inflammatory hypo/hyper pigmentation may be present". Grades of "4" are severe: "Abundant prurigo nodules. Marked nodule elevation."
Time frame: Baseline (week 0) and 12 weeks
Quality of Life as Assessed by the EuroQoL 5-Dimension at Baseline and Week 12
Quality of life as assessed by EuroQoL 5-Dimension (EQ-5D). The 3 level version of the EQ-5D (EQ-5D-3L) assesses degree of debilitation in 5 major aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three possible answers. These answers equate to: "No problems" or "Some/Moderate Problems" or "Severe/Extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. A unique health state is then defined by combining one level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code. A total of 243 possible health states codes is defined in this way. State 11111 indicates no problems on any of the five dimensions. The patient then rates how good or bad their health is on that day from a range from 0 the worst health you can imagine, to 100 the best health you can imagine.
Time frame: Baseline (week 0) and 12 weeks
Depression as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12
Depression as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to depression. Each item scored from 0-3 with higher scores indicating higher depression. Total score range 0-21.
Time frame: Baseline (week 0) and 12 weeks
Anxiety as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12
Anxiety as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to anxiety. Each item scored from 0-3 with higher scores indicating higher anxiety. Total score range 0-21.
Time frame: Baseline (week 0) and 12 weeks
Sleep Disturbance as Assessed by the SD-NRS at Baseline and Week 12
Average sleep disturbance from Week 0 and Week 12 as assessed by (SD) NRS. The SD-NRS is an 11-point scale (0 -10) with higher scores indicating greater sleep disturbance.
Time frame: Baseline (week 0) and 12 weeks
Itch Intensity in Patients With Underlying Atopy at Baseline and Week 12
Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients with underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.
Time frame: Baseline (week 0) and 12 weeks
Itch Intensity in Patients Without Underlying Atopy at Baseline and Week 12
Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients without underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy is defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.
Time frame: Baseline (week 0) and 12 weeks
Itch Intensity in CPUO Patients With High Eosinophilia at Baseline and Week 12
Itch intensity as measured by PP-NRS in CPUO patients with high eosinophilia (greater than 500 eosinophils per micro-liter of blood). The PP-NRS is an 11-point single self-report item on a scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.
Time frame: Baseline (week 0) and 12 weeks
Cutaneous Biomarker Analysis - Gene Set Variation Analysis (GSVA), at Baseline and Week 12
Lesional and non-lesional skin biopsies will be compared for Type 1/2/17/22 T Helper (Th) Th1/Th2/Th17/Th22 polarization before and after treatment. PN and CPUO patients had biopsies collected at Week 0 and at Week 12. PN patients had two biopsies collected: a lesional site and a non-lesional biopsy close by for comparison. The CPUO patients only had one biopsy collected at the timepoints because there are no visible lesions. CPUO will be compared from week 0 to week 12. PN will compare Lesional to non Lesional at Week 0. PN will compare Lesional to Non Lesional at Week 12. GSVA will compare gene set enrichment scores as a function of gene pathway expression which range from -1 to 1. Lower scores indicate down regulation of the gene set, and higher scores indicate up regulation.
Time frame: Baseline (week 0) and 12 weeks
Systemic Biomarker Analysis - Gene Set Variation Analysis (GSVA), at Baseline and Week 12
Plasma cytokines will be analyzed for TH1/Th2/Th17/Th22 polarization before and after treatment. This outcome was posted in error. It is not appropriate to perform GSVA of plasma cytokines. It is best practice to limit GSVA to RNASeq.
Time frame: Baseline and 12 weeks
Patients were recruited by referral or at Johns Hopkins Dermatology clinic between September 2021 and March 2022
| Milestone | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Started | 10 | 10 |
| End of intervention period. week 12: per protocol population | 10 | 10 |
| Follow-up period (4 weeks) | 10 | 8 |
| Completed | 10 | 8 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Percent change in weekly average PP-NRS at Week 12. PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.
| percent change | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12 | -78.26 (-118.48 to -38.09) | -53.66 (-98.76 to -8.55) |
Number of subjects achieving at least a 4-point reduction from baseline in weekly average PP-NRS at Week 12. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.
| Participants | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Number of Subjects Achieving a Reduction in Weekly Average PP-NRS From Baseline to Week 12 | 8 | 6 |
Assess itch severity as assessed by 5-D pruritus scale. The 5-D pruritus scale scores pruritus over the past 2 weeks along 5 dimensions: duration, degree, direction, disability and distribution. Duration, degree and direction are scored from 1 to 5, with "1" indicating better control and resolution of symptoms, and "5" indicating increased intensity, severity and worsening. Disability is assessed in Leisure/Social, housework/errands, and work/school with scores ranging from N/A, and 1-5, with "1" indicating that itch never affects the activity, and "5" meaning that itch always affects this activity. The scores of each of the 5 domains are achieved separately and then summed together to obtain a total score. Scores can range between 5 no pruritus, and 25 most severe pruritus.
| score on a scale | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Week 0 | 18.60 (14.98 to 22.22) | 17.40 (14.89 to 19.91) |
| Week 12 | 9.20 (7.59 to 10.81) | 11.30 (6.40 to 16.20) |
Quality of life as assessed by the Dermatology Quality of Life Index (DLQI). The DLQI is 10 questions used to assess impact of skin disease. Scores range from 0-30, with "0" corresponding to best quality of life, and "30" corresponding to worst quality of life.
| score on a scale | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Week 0 | 19.0 (13.30 to 24.70) | 9.60 (6.40 to 12.80) |
| Week 12 | 8.90 (4.31 to 13.49) | 4.90 (2.68 to 7.12) |
Pruriginous lesions as assessed by the Prurigo Activity Score (PAS). The PAS is a 7-item questionnaire that assesses the number, distribution and activity of pruriginous lesions. The score is calculated via summation of the scoring values, added up with 123 and afterwards divided by 10. This results in a range of values from 1.3 to 21.3.
| score on a scale | Prurigo Nodularis |
|---|---|
| Week 0 | 14.76 (13.04 to 16.48) |
| Week 12 | 9.32 (6.57 to 12.07) |
Itch-scratching behavior as assessed by Patient Reported Outcomes Measurement Information System (PROMIS®) Itch Questionnaire (PIQ) T-Score: Scratching. The PIQ T-Score: Scratching, is comprised of 5 questions to assess Itch-Scratching Behavior over the past 7 days. Scores for each question range from 1-5, Score range of 5-25 with scores of "1" indicating less scratching behavior and scores of "5" indicating the greatest scratching behavior. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Itch, a T-score of 60 is one SD worse than average. By comparison, an Itch T-score of 40 is one SD better than average For PROMIS, the T-scores have a mean (SD) of 50 (10) for adults in the US experiencing itch for any reason.
| T-score | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Week 0 | 53.76 (48.74 to 58.78) | 45.60 (41.57 to 49.63) |
| Week 12 | 41.03 (32.67 to 49.39) | 35.72 (30.28 to 41.16) |
Number of baseline prurigo nodules over time. As part of the Prurigo Activity Score, lesions are counted in a representative body region. Lesion count within the representative area at Week 0 was compared to lesion count in the representative area at Week 12.
| Lesion count | Prurigo Nodularis |
|---|---|
| Week 0 | 14.90 (9.21 to 20.59) |
| Week 12 | 4.70 (2.59 to 6.81) |
Prurigo nodule severity using the Investigator's Global Assessment (IGA). The IGA is a physician scale assessing the number of nodules a Prurigo Nodularis (PN) patient has. Patients receive a score between 0 and 4, where "0" is clear: "No prurigo nodules. Post-inflammatory hypo/hyper pigmentation may be present". Grades of "4" are severe: "Abundant prurigo nodules. Marked nodule elevation."
| score on a scale | Prurigo Nodularis |
|---|---|
| Week 0 | 3.60 (3.23 to 3.97) |
| Week 12 | 2.50 (1.99 to 3.01) |
Quality of life as assessed by EuroQoL 5-Dimension (EQ-5D). The 3 level version of the EQ-5D (EQ-5D-3L) assesses degree of debilitation in 5 major aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three possible answers. These answers equate to: "No problems" or "Some/Moderate Problems" or "Severe/Extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. A unique health state is then defined by combining one level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code. A total of 243 possible health states codes is defined in this way. State 11111 indicates no problems on any of the five dimensions. The patient then rates how good or bad their health is on that day from a range from 0 the worst health you can imagine, to 100 the best health you can imagine.
| score on a scale | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Week 0 | 0.60 (0.33 to 0.87) | 0.74 (0.55 to 0.93) |
| Week 12 | 0.75 (0.52 to 0.99) | 0.86 (0.67 to 1.05) |
Depression as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to depression. Each item scored from 0-3 with higher scores indicating higher depression. Total score range 0-21.
| score on a scale | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Week 0 | 6.90 (3.42 to 10.38) | 4.20 (0.93 to 7.47) |
| Week 12 | 3.30 (0.398 to 6.202) | 3.10 (0.310 to 5.890) |
Anxiety as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to anxiety. Each item scored from 0-3 with higher scores indicating higher anxiety. Total score range 0-21.
| score on a scale | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Week 0 | 6.60 (2.62 to 10.58) | 4.30 (0.061 to 8.54) |
| Week 12 | 5.90 (2.61 to 9.20) | 4.30 (0.27 to 8.33) |
Average sleep disturbance from Week 0 and Week 12 as assessed by (SD) NRS. The SD-NRS is an 11-point scale (0 -10) with higher scores indicating greater sleep disturbance.
| score on a scale | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Week 0 | 7.20 (5.52 to 8.88) | 5.10 (2.66 to 7.54) |
| Week 12 | 2.40 (-0.060 to 4.86) | 2.80 (-0.017 to 5.62) |
Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients with underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.
| score on a scale | Prurigo Nodularis |
|---|---|
| Week 0 | 9.67 (8.23 to 11.10) |
| Week 12 | 0.67 (-2.20 to 3.54) |
Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients without underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy is defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.
| score on a scale | Prurigo Nodularis |
|---|---|
| Week 0 | 9.00 (7.93 to 10.07) |
| Week 12 | 2.57 (0.075 to 5.07) |
Itch intensity as measured by PP-NRS in CPUO patients with high eosinophilia (greater than 500 eosinophils per micro-liter of blood). The PP-NRS is an 11-point single self-report item on a scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.
No measurements were reported for this outcome.
Lesional and non-lesional skin biopsies will be compared for Type 1/2/17/22 T Helper (Th) Th1/Th2/Th17/Th22 polarization before and after treatment. PN and CPUO patients had biopsies collected at Week 0 and at Week 12. PN patients had two biopsies collected: a lesional site and a non-lesional biopsy close by for comparison. The CPUO patients only had one biopsy collected at the timepoints because there are no visible lesions. CPUO will be compared from week 0 to week 12. PN will compare Lesional to non Lesional at Week 0. PN will compare Lesional to Non Lesional at Week 12. GSVA will compare gene set enrichment scores as a function of gene pathway expression which range from -1 to 1. Lower scores indicate down regulation of the gene set, and higher scores indicate up regulation.
| score on a scale | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| Th1 Lesional Week 0 | 0.35 (0.0035 to 0.69) | 0.27 (0.076 to 0.46) |
| Th1 Non Lesional Week 0 | -0.085 (-0.31 to 0.14) | — |
| Th1 Lesional Week 12 | 0.045 (-0.31 to 0.40) | -0.31 (-0.49 to -0.14) |
| Th1 Non Lesional Week 12 | -0.36 (-0.70 to -0.021) | — |
| Th2 Lesional Week 0 | 0.22 (-0.047 to 0.49) | 0.17 (0.016 to 0.32) |
| Th2 Non Lesional Week 0 | -0.11 (-0.31 to 0.086) | — |
| Th2 Lesional Week 12 | 0.10 (-0.16 to 0.37) | -0.20 (-0.32 to -0.083) |
| Th2 Non Lesional Week 12 | -0.18 (-0.44 to 0.080) | — |
| Th17 Lesional Week 0 | 0.29 (0.048 to 0.52) | 0.12 (-0.10 to 0.33) |
| Th17 Non Lesional Week 0 | -0.29 (-0.52 to -0.062) | — |
| Th17 Lesional Week 12 | 0.20 (-0.16 to 0.57) | -0.099 (-0.25 to 0.050) |
| Th17 Non Lesional Week 12 | -0.083 (-0.45 to 0.29) | — |
| Th22 Lesional Week 0 | 0.23 (-0.060 to 0.52) | 0.23 (0.048 to 0.42) |
| Th22 Non Lesional Week 0 | -0.29 (-0.50 to -0.071) | — |
| Th22 Lesional Week 12 | 0.25 (-0.060 to 0.55) | -0.15 (-0.34 to 0.034) |
| Th22 Non Lesional Week 12 | -0.16 (-0.49 to 0.17) | — |
Plasma cytokines will be analyzed for TH1/Th2/Th17/Th22 polarization before and after treatment. This outcome was posted in error. It is not appropriate to perform GSVA of plasma cytokines. It is best practice to limit GSVA to RNASeq.
No measurements were reported for this outcome.
Collected over From the first date of abrocitinib administration to the last date of abrocitinib administration + 4 week follow up, up to 16 weeks total.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prurigo Nodularis | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Chronic Pruritus of Unknown Origin | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | Prurigo Nodularis | Chronic Pruritus of Unknown Origin |
|---|---|---|
| HeadacheNervous system disorders | 1/10 | 0/10 |
| NauseaGastrointestinal disorders | 1/10 | 0/10 |
| FolliculitisSkin and subcutaneous tissue disorders | 0/10 | 1/10 |
| Acneiform EruptionSkin and subcutaneous tissue disorders | 1/10 | 1/10 |
| Sore throatInfections and infestations | 1/10 | 0/10 |
| Herpes LabialisInfections and infestations | 0/10 | 1/10 |
| Nasal CongestionInfections and infestations | 1/10 | 0/10 |
| Age, Continuous(years) | Prurigo Nodularis | Chronic Pruritus of Unknown Origin | Total |
|---|---|---|---|
| Mean | 58.6 ± 13.1 | 70.7 ± 5.6 | 64.7 ± 11.6 |
| Sex: Female, Male(Participants) | Prurigo Nodularis | Chronic Pruritus of Unknown Origin | Total |
|---|---|---|---|
| Female | 10 | 2 | 12 |
| Male | 0 | 8 | 8 |
| Race (NIH/OMB)(Participants) | Prurigo Nodularis | Chronic Pruritus of Unknown Origin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 0 | 5 |
| White | 5 | 10 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Prurigo Nodularis | Chronic Pruritus of Unknown Origin | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Jul 2022, 10 months.
Results were first posted in Jul 2023, 11 months after primary completion.
Of 52 phase 2 interventional studies under Pruritus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 31. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib